<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800045</url>
  </required_header>
  <id_info>
    <org_study_id>P11-05 / Pitolisant</org_study_id>
    <secondary_id>2012-003076-39</secondary_id>
    <nct_id>NCT01800045</nct_id>
  </id_info>
  <brief_title>Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)</brief_title>
  <official_title>A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, randomized, parallel groups study of Pitolisant versus placebo, in narcoleptic
      patients experiencing EDS, and cataplexy (minimum of 3 complete or partial cataplexy attacks
      per week).

      The patients will be treated during 7 weeks with Pitolisant or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment period (7 weeks double blind) will aim at demonstrating the efficacy of
      Pitolisant on the number of cataplexy attacks and the Excessive Daytime Sleepiness by
      verifying whether the results of Pitolisant are superior to those of placebo.

      The safety will also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of anticataplectic efficacy</measure>
    <time_frame>At week 7</time_frame>
    <description>Measure of anticataplectic efficacy assessed by the change in the average number of cataplexy attacks per week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Excessive Daytime Sleepiness assessment</measure>
    <time_frame>At week 7</time_frame>
    <description>Excessive Daytime Sleepiness assessment by evaluation of ESS score, and other questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>11 weeks</time_frame>
    <description>Safety assessment thanks to AE recording, vitals signs assessment, ECG...</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Narcolepsy With Cataplexy</condition>
  <condition>Excessive Daytime Sleepiness</condition>
  <arm_group>
    <arm_group_label>Pitolisant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitolisant at 5, 10, 20 or 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules of placebo containing lactose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitolisant</intervention_name>
    <description>1 capsule in the morning before breakfast</description>
    <arm_group_label>Pitolisant</arm_group_label>
    <other_name>BF2.649</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule in the morning before breakfast</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Capsules of placebo containing lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Narcoleptic with cataplexy : at least 3 weekly cataplexy attacks

          -  ESS &gt; or = 12

          -  ICF signed and dated

        Main Exclusion Criteria:

          -  Other conditions that could generate EDS

          -  Psychological and neurological disorders

          -  Acute or chronic severe disease

          -  Treatment by prohibited medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyne De Paillette, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Bioprojet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Health Center</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Narcolepsy</keyword>
  <keyword>Cataplexy</keyword>
  <keyword>Sleep disorder</keyword>
  <keyword>Excessive daytime sleepiness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

